Unicycive Therapeutics (UNCY) announced the FDA has issued a CRL for its New Drug Application for OLC to treat hyperphosphatemia in patients with chronic kidney disease on dialysis. Oxylanthanum Carbonate - or OLC - is an investigational oral phosphate binder that leverages nanoparticle technology to deliver high phosphate binding potency, reducing the number and size of pills that patients must take to treat hyperphosphatemia in patients with chronic kidney disease on dialysis. The CRL cited deficiencies previously identified at a third-party manufacturing vendor unrelated to Oxylanthanum Carbonate.
"We plan to immediately seek a Type A meeting with the Agency to gain alignment on the best strategy to ensure rapid resolution of the CRL," said Shalabh Gupta, CEO of Unicycive.
Unicycive currently has an unaudited cash balance of approximately $20.7 million, with cash runway currently expected into the second half of 2026.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.